Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 3/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.44 |
| ▸ | MLNR | O43193 | 5/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PLD2 | O14939 | 1/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495857 | 0.89 | HPGDS (0.53) | HPGDSGABRA5WNT3A | |
| SCHEMBL16495442 | 0.88 | GABRA5 (0.60) | RAB9AKMT2AHPGDSGABRA5KDM4E | |
| SCHEMBL16496422 | 0.87 | HPGDS (0.51) | HPGDSGABRA5WNT3APRKAA2 | |
| SCHEMBL16495558 | 0.85 | HPGDS (0.53) | RAB9AKMT2AHPGDSGABRA5KDM4E | |
| SCHEMBL2072422 | 0.84 | HPGDS (0.54) | RAB9AKMT2AHPGDSGABRA5KDM4E | |
| SCHEMBL16496173 | 0.84 | HPGDS (0.52) | RAB9AKMT2AHPGDSGABRA5ALDH1A1 | |
| SCHEMBL16496048 | 0.83 | HPGDS (0.60) | KMT2AHPGDSALDH1A1 | |
| SCHEMBL16495429 | 0.82 | CD274 (0.60) | HPGDSWNT3A | |
| SCHEMBL16495625 | 0.82 | HPGDS (0.59) | KMT2AHPGDS | |
| SCHEMBL16495519 | 0.80 | HPGDS (0.65) | HPGDSWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | RAB9A 2122/4885KMT2A 3206/4885HPGDS 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.